All articles by GlobalData Healthcare

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Chimeric antigen receptor (CAR) T cell therapies have made remarkable strides in treating high-risk B-cell malignancies since the first CAR-T,…
AD/PD 2025: DHTs can detect disease progression in patients with early Parkinson’s

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, Roche outlined the effectiveness of digital health technologies (DHTs)…
IO360 summit: CAR-T cell therapy applications beyond blood cancer

Chimeric antigen receptor (CAR) T cell therapies have made remarkable strides in treating high-risk B-cell malignancies since the first CAR-T,…
Weight loss implants to increase compliance and cut admin burden for patients

Obesity is a chronic metabolic disease characterised by excess body weight and comorbidities that can become life-threatening. The obesity treatment…
ACC 2025: GLP-1RAs may reduce incidence of AF/flutter and stroke in diabetic patients

At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results from a study by O’Neill and colleagues…

ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity

At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, further results and analyses were presented from the…
CNS market resurgence: a decade-long slump ends with $80bn milestone

In 2025, the central nervous system (CNS) market is forecast to surpass $80bn in sales for the first time since…
Large pharma drug licensing from China hits high at 28% in 2024

Licensing agreements for Chinese drug candidates have surged, with large pharma in-licensing 28% of innovator drugs from Chinese biopharma companies…
ACC 2025: Imbria’s ninerafaxstat data shows potential for cardiometabolic HFpEF

On 29 March, Dr. Sarah Birkhoelzer, presented results from the open-label, Phase IIa trial of ninerafaxstat during a moderated poster…
Biopharma IPOs showed signs of recovery in 2024

Biopharmaceutical initial public offerings (IPOs) saw an upturn in 2024, with 50 completed IPOs raising a total of $8.52 billion…